Invest. Engage. Save.

Rss

Diving In

Posted by: BIO Ventures for Global Health on 8/27/2010 | 0 Comments
There’s been a lot of talk about the Pool for Open Innovation against Neglected Tropical Diseases, but we understand that many product developers are still wondering exactly how it will benefit them. No more! Today, we launched www.ntdpool.org, a website that explains more about the Pool, its mission, and the patents and know-how it contains.
Categories: Incentives News Partnering

North-South Partnership

Posted by: BIO Ventures for Global Health on 5/3/2010 | 0 Comments
Emerging markets are fast becoming a global health research and development powerhouse. Just ask Dr. Mamphela Ramphele of South Africa's Technology Innovation Agency. At yesterday's Partnering for Global Health Forum, she said that global health R&D is not simply a question of what the 'North can do for the South,' but what the North and the South can partner to achieve to fast track the development of new drugs and to mine the huge markets that are opening up. Read more...
Categories: Meetings Partnering

Don't Blame the Market

Posted by: BIO Ventures for Global Health on 5/3/2010 | 0 Comments
During our luncheon plenary, Dr. Nils Daulaire from the U.S. Dept. of Health and Human Services said that we are not looking at failure, but rather the natural workings of the market, where you have customers who cannot afford to purchase medicines. Rather than talk about failure, we must talk about ways to get around developing world limitations with something more than the invisible hand. Read more...
Categories: Meetings News Partnering

Turning Vision Into Reality

Posted by: BIO Ventures for Global Health on 5/3/2010 | 0 Comments
Dr. Gina Rabinovich has a vision: A little girl who has grown up without fear of dying of childhood illness, holding her immunization card for malaria, tuberculosis, and other diseases in her hand. Where she is from does not matter. Learn more about Dr. Rabinovich's opening plenary speech and how the Partnering for Global Health Forum has much to offer can make that vision a reality.
Categories: Meetings News Partnering

Crossing the Valley of Death

Posted by: BIO Ventures for Global Health on 4/13/2010 | 1 Comment
FasterCures, a nonprofit think tank that works across sectors and diseases to improve the effectiveness and efficiency of medical research enterprises, held a Forum this past Wednesday to draw attention to a part of the Patient Protection and Affordable Care Act – the Cures Acceleration Network – that could make a big difference for neglected diseases.
Categories: Incentives Meetings News Partnering

Partnering 101

Posted by: BIO Ventures for Global Health on 3/8/2010 | 1 Comment
The BIO One-on-One Partnering™ system opened last Monday. The system is your secretary, your portal, and your who’s who list for the partnering activities that take place during the BIO Business Forum, May 4-6. In 2009 a record-setting 14,202 30-minute partnering meetings took place through the partnering system. And with over 1,000 organizations in the system, there can be a lot of information to sort through in order to make sure that you make the most of partnering opportunities during the event. Here are some tips to on how to make the most of your time.
Categories: Meetings Partnering
Page:

Blog Home
  
  

Recent Comments

by php flash chat on Speed Dating to Save Lives
"It was my first visit to your blog, but I admire time and effort you put into it! I have enjoyed reading many of your articles, looks like you are a professional writer! Well done! James, " Read more »

by simon on The Most Important Hire in Global Health
"I'd like to comment on the fact that the term "cost-effective" vaccines is not meaningful, since cost-effectiveness always depends on the Willigness to Pay of a given coutnry (which WHO recommends to be 1-3xGDP per capita). E.g. while in UK a medicines/vaccine that has incremental cost-effectiveness ratio of 43,000-130,000 USD/QALY will be considered "cost-effective", it will not be the case in India where the threshold is 1-3xGDP=1,000-3,000 USD/QALY. It means that the same vaccine would need to be 43x cheaper in India than in UK to be cost-effective. I believe that the future of developing countries will depend on their ability to develop vaccines locally and sell them at local prices. I am currently involved in a research project in India which aims at understanding the challenges of entrepreneurship and its role in affordable healthcare in the future. Best regards " Read more »

by Mark H on Trademark of Innovation
"Often the pharmaceutical companies are seen as evil because they do not do enough to help the poor by giving away medicines or licence rights. But we must consider two things: 1 they are commecial companies and have legal obligations towards their shareholders i.e. their prime concern is making money 2 these companies invest a vastly greater amount of money in R&D than the government. As a result their R&D occasionally finds cures inadvertently for other diseases - even if they are not actively trying to create the right medicine. So how do you create an incentive for the most effective creator of new innovative cures whose primary goal is to make money (like all companies)? Well the answer seems obvious - reward them with tax benefits that would help push them above their competitors. Whilst you could argue that this would prevent the government from reaping the benefits (tax) you could also say that the competition created would drive innovation and spending in the private sector which would improve the economy. A win win win situation - pharmaceuticals, government, developing countries!" Read more »

  

Tag Cloud